newsfilter
← Latest News
GlobeNewswire·

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to